{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:51:37Z","timestamp":1781599897289,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031665","name":"Medical Research Center, Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","award":["MRC-01-21-301"],"award-info":[{"award-number":["MRC-01-21-301"]}],"id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejphar.2025.178329","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:18:43Z","timestamp":1762388323000},"page":"178329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Selective induction of apoptosis in T-cell acute lymphoblastic leukemia by pristimerin through dual PI3K\/AKT pathway inhibition and ROS generation"],"prefix":"10.1016","volume":"1008","author":[{"given":"Shilpa","family":"Kuttikrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahwa","family":"Mariyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummu","family":"Habeeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu J.","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti S.","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaloun","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-7496","authenticated-orcid":false,"given":"Said","family":"Dermime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammira S.","family":"Al Shabeeb Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-6275","authenticated-orcid":false,"given":"Ajaz A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul W.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-6710","authenticated-orcid":false,"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178329_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fonc.2019.00285","article-title":"Sanguinarine induces apoptosis pathway in multiple myeloma cell lines via inhibition of the JaK2\/STAT3 signaling","volume":"9","author":"Akhtar","year":"2019","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.ejphar.2025.178329_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225621","article-title":"Guggulsterone induces apoptosis in multiple myeloma cells by targeting high mobility group box 1 via janus activated kinase\/signal transducer and activator of transcription pathway","volume":"14","author":"Akhtar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2025.178329_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113950","article-title":"Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways","volume":"156","author":"Al-Tamimi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"34","key":"10.1016\/j.ejphar.2025.178329_bib4","doi-asserted-by":"crossref","first-page":"55690","DOI":"10.18632\/oncotarget.10984","article-title":"Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K\/Akt\/mTOR pathway in T-cell acute lymphoblastic leukemia","volume":"7","author":"Alameen","year":"2016","journal-title":"Oncotarget"},{"issue":"Pt A","key":"10.1016\/j.ejphar.2025.178329_bib5","article-title":"Azithromycin downregulates ICOS (CD278) and OX40 (CD134) expression and mTOR activity of TCR-Activated T cells to inhibit proliferation","volume":"124","author":"Ansari","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.178329_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.vh.2022.09.002","article-title":"The antioxidant glutathione","volume":"121","author":"Averill-Bates","year":"2023","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejphar.2025.178329_bib7","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8829.1","article-title":"An overview of cutaneous T cell lymphomas","volume":"5","author":"Bagherani","year":"2016","journal-title":"F1000Res"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178329_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050598","article-title":"Exploring synergistic interactions between natural compounds and conventional chemotherapeutic drugs in preclinical models of lung cancer","volume":"17","author":"Bota","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178329_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09519","article-title":"Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies","volume":"8","author":"Castaneda","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.178329_bib10","article-title":"Cellular and molecular mechanisms of pristimerin in cancer therapy: recent advances","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178329_bib11","first-page":"239","article-title":"Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer","volume":"3","author":"Chu QxaXZea","year":"2024","journal-title":"Acta Materia Medica"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer drug discovery based on natural products: from computational approaches to clinical studies","volume":"12","author":"Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"W1","key":"10.1016\/j.ejphar.2025.178329_bib14","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178329_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102492","article-title":"Inhibiting the inhibitors: development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck","volume":"113","author":"Ferris","year":"2023","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178329_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-016-0823-y","article-title":"Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells","volume":"14","author":"Iskandarani","year":"2016","journal-title":"J. Transl. Med."},{"issue":"7\u20138","key":"10.1016\/j.ejphar.2025.178329_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10495-022-01735-y","article-title":"Programmed cell death detection methods: a systematic review and a categorical comparison","volume":"27","author":"Kari","year":"2022","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178329_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1550-2783-2-2-38","article-title":"The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress","volume":"2","author":"Kerksick","year":"2005","journal-title":"J. Int. Soc. Sports Nutr."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib20","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41467-018-04214-8","article-title":"Molecular mechanism of influenza A NS1-mediated TRIM25 recognition and inhibition","volume":"9","author":"Koliopoulos","year":"2018","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.ejphar.2025.178329_bib21","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/bloodadvances.2020001822","article-title":"T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?","volume":"4","author":"Kroeze","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejphar.2025.178329_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fonc.2019.00484","article-title":"Curcumin induces apoptotic cell death via inhibition of PI3-Kinase\/AKT pathway in B-Precursor acute lymphoblastic leukemia","volume":"9","author":"Kuttikrishnan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2025.178329_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbrc.2022.02.071","article-title":"Anticancer activity of neosetophomone B by targeting AKT\/SKP2\/MTH1 axis in leukemic cells","volume":"601","author":"Kuttikrishnan","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178329_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cbin.12101","article-title":"Neosetophomone B induces apoptosis in multiple myeloma cells via targeting of AKT\/SKP2 signaling pathway","volume":"48","author":"Kuttikrishnan","year":"2024","journal-title":"Cell Biol. Int."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178329_bib25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/ijms24021689","article-title":"CLC-Pred 2.0: a freely available web application for in silico prediction of human cell line cytotoxicity and molecular mechanisms of action for druglike compounds","volume":"24","author":"Lagunin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178329_bib26","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.16439.1","article-title":"Recent advances in understanding inhibitor of apoptosis proteins","volume":"7","author":"Lalaoui","year":"2018","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12885-016-2730-2","article-title":"Anti-cancer effect of pristimerin by inhibition of HIF-1alpha involves the SPHK-1 pathway in hypoxic prostate cancer cells","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2025.178329_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fphar.2019.00746","article-title":"Anti-cancer effects of pristimerin and the mechanisms: a critical review","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejphar.2025.178329_bib29","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.7150\/jca.44431","article-title":"Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 lung cancer cells","volume":"11","author":"Li","year":"2020","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178329_bib30","first-page":"5","article-title":"Pristimerin induces apoptosis in prostate cancer cells by down-regulating Bcl-2 through ROS-Dependent ubiquitin-proteasomal degradation pathway","author":"Liu","year":"2013","journal-title":"J. Carcinog. Mutagen."},{"issue":"6 Suppl. 1","key":"10.1016\/j.ejphar.2025.178329_bib31","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bj.2020.07.004","article-title":"Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin beta3","volume":"44","author":"Liu","year":"2021","journal-title":"Biomed. J."},{"issue":"0","key":"10.1016\/j.ejphar.2025.178329_bib32","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/07357907.2024.2445528","article-title":"A comprehensive Insight into apoptosis: molecular mechanisms, signaling pathways, and modulating therapeutics","volume":"43","author":"Mosadegh","year":"2025","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu. Rev. Pathol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178329_bib35","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2025.178329_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121110","article-title":"Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy","volume":"277","author":"Niu","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.31083\/j.fbl2901040","article-title":"Sanguinarine triggers apoptosis in cutaneous squamous cell carcinoma cells through reactive oxygen species-dependent c-Jun N-Terminal kinase signaling pathway","volume":"29","author":"Patil","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178329_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178329_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180895","article-title":"Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase\/AKT signaling by embelin suppresses growth of leukemic cells","volume":"12","author":"Prabhu","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178329_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050578","article-title":"Anticancer potential and molecular targets of pristimerin in human malignancies","volume":"17","author":"Prabhu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178329_bib41","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in lung cancer: mechanisms and therapeutic targeting","volume":"16","author":"Qiang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178329_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26051868","article-title":"A comprehensive review of nanoparticle-based drug delivery for modulating PI3K\/AKT\/mTOR-Mediated autophagy in cancer","volume":"26","author":"Rahman","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178329_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004586","article-title":"AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility","volume":"11","author":"Ravindranath","year":"2015","journal-title":"PLoS Comput. Biol."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178329_bib45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/embor.2009.219","article-title":"VDAC2 is required for truncated BID-induced mitochondrial apoptosis by recruiting BAK to the mitochondria","volume":"10","author":"Roy","year":"2009","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/13880209.2021.1903047","article-title":"Cytotoxic activity of standardized extracts, a fraction, and individual secondary metabolites from fenugreek seeds against SKOV-3, HeLa and MOLT-4 cell lines","volume":"59","author":"Stefanowicz-Hajduk","year":"2021","journal-title":"Pharm. Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178329_bib47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178329_bib48","first-page":"3017","article-title":"Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G(1) phase arrest and MAPK\/Erk1\/2 and Akt signaling inhibition","volume":"17","author":"Wu","year":"2019","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178329_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jcb.21399","article-title":"Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells","volume":"103","author":"Yang","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2025.178329_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.biopha.2016.02.003","article-title":"Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells","volume":"79","author":"Yousef","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178329_bib51","first-page":"1382","article-title":"Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a\/Akt\/GSK3beta signaling pathway and suppressing autophagy in lung cancer cells","volume":"43","author":"Zhang","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178329_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41420-019-0208-0","article-title":"Pristimerin induces apoptosis and autophagy via activation of ROS\/ASK1\/JNK pathway in human breast cancer in vitro and in vivo","volume":"5","author":"Zhao","year":"2019","journal-title":"Cell Death Discov."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925010830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:26:34Z","timestamp":1773318394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925010830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"alternative-id":["S0014299925010830"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178329","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective induction of apoptosis in T-cell acute lymphoblastic leukemia by pristimerin through dual PI3K\/AKT pathway inhibition and ROS generation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178329"}}